Figure 3 — RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Research Paper|Volume 16, Issue 17|pp. 12392–12413

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Back to articleFigure 3(3 of 11)

100%

Figure 3.Enrichment analysis of RPL22L1 (GSEA). (A) Ribosome. (B) Spliceosome. (C) Cell cycle. (D) Huntington’s disease. (E) Oxidative phosphorylation. (F) Parkinsons disease. (G) Olfactory transduction. (H) Pyrimidine metabolism. (I) Alzheimer's disease. NES, which stands for normalized ES, and FDR, which stands for false discovery rate, were utilized in this study.